Boiron USA (BOI) Stock Price & News

Why is BOI up 2,36%?

Dive Deeper

BOI:EPA

Boiron USA

19,50 €

+2,36%

(+0,45) 1D

5-ноя., 17:35:17 GMT+1 · EUR

All symbols

	Symbol	Price	Change	% Change

Generating top insights for BOI...

Open

19,10 €

High

19,95 €

Low

19,10 €

Mkt. cap

338,78 млн

Avg. vol.

5,00 миң

Volume

3,69 миң

P/E ratio

12,93

52-wk high

32,25 €

52-wk low

16,90 €

EPS

1,51 €

Shares outstanding

17,55 млн

No. of employees

3 миң

Open

19,10 €

High

19,95 €

Low

19,10 €

Mkt. cap

338,78 млн

Avg. vol.

5,00 миң

Volume

3,69 миң

P/E ratio

12,93

52-wk high

32,25 €

52-wk low

16,90 €

EPS

1,51 €

Shares outstanding

17,55 млн

No. of employees

3 миң

Related stocks

Bank of East Asia Ltd

News stories

From web sources and news partners

Quantisnow

21 мүнөт мурун

TransUnion Appoints David Gilbert as Interim Chief Financial Officer

FinancialContent

40 мүнөт мурун

FinancialContent - Kratos (NASDAQ:KTOS) posts Q3 2026 sales in line with estimates, quarterly revenue guidance slightly exceeds expectations

KCBY

35 мүнөт мурун

Wall Street weighs economic fallout from Democrats' midterm sweep

Fox Business

55 мүнөт мурун

Stocks plunge as Dem midterm sweep fuels AI regulatory concerns

Profile

Boiron is a manufacturer of homeopathic products, headquartered in France and with an operating presence in 59 countries worldwide. It is the largest manufacturer of homeopathic products in the world. In 2004, it had a workforce of 2,779 and turnover of € 313 million. It is a member of the CAC Small stock index. In June 2005, the firm acquired Dolisos Laboratories, then the world's second largest manufacturer of homeopathic preparations. Products of Boiron include mono- and poly-preparations, which Boiron refer to as "proprietary drugs". Homeopathy is a pseudoscience with no evidence of effectiveness for stated claims or plausible mechanism of medicinal effect, and several class action lawsuits have been filed on behalf of consumers claiming that Boiron's homeopathic products, including Children's Coldcalm and Oscillococcinum, are useless and Boiron's marketing of these products is deceptive. Wikipedia

About Boiron USA

CEO-

Employees2,62 миң

Founded1932-ж., 7-июн.

Headquarters-

SectorHealth Care

IndustryPharmaceutical industry

Websiteboiron.fr

All values in EUR	2025-ж. сен.	2025-ж. дек.	2026-ж. мар.	2026-ж. июн.
Revenue	127,73 млн	127,73 млн	120,16 млн	120,16 млн
Cost of goods sold	35,40 млн	35,40 млн	33,53 млн	33,53 млн
Cost of revenue	35,40 млн	35,40 млн	33,53 млн	33,53 млн
Research and development expenses	1,56 млн	1,56 млн	1,44 млн	1,44 млн
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	79,26 млн	79,26 млн	79,95 млн	79,95 млн
Operating expense	77,52 млн	77,52 млн	81,88 млн	81,88 млн
Total operating expenses	112,92 млн	112,92 млн	115,41 млн	115,41 млн
Operating income	14,81 млн	14,81 млн	4,76 млн	4,76 млн
Other non operating income	-1,13 млн	-1,13 млн	-2,29 млн	-2,29 млн
EBT including unusual items	13,82 млн	13,82 млн	4,02 млн	4,02 млн
EBT excluding unusual items	13,16 млн	13,16 млн	2,75 млн	2,75 млн
Income tax expense	3,18 млн	3,18 млн	1,56 млн	1,56 млн
Effective tax rate	22,99%	22,99%	38,90%	38,90%
Other operating expenses	-3,30 млн	-3,30 млн	488,00 миң	488,00 миң
Net income	10,64 млн	10,64 млн	2,46 млн	2,46 млн
Net profit margin	8,33%	8,33%	2,04%	2,04%
Earnings per share	-	-	-	-
Interest and investment income	653,00 миң	653,00 миң	636,50 миң	636,50 миң
Interest expense	-335,00 миң	-335,00 миң	-410,00 миң	-410,00 миң
Net interest expenses	318,00 миң	318,00 миң	226,50 миң	226,50 миң
Depreciation and amortization charges	-	-	-	-
EBITDA	18,06 млн	18,06 млн	11,17 млн	11,17 млн
Gain or loss from assets sale	-446,00 миң	-446,00 миң	-	-

Finance

Ask anything